Key facts
- Notable investors include Suzhou Wujiang Venture Capital, Shenzhen Rurisheng Equity Investment, Jiangsu Jinqiao Private Equity Fund Management, Kangli Elevator, Sihai New Material Fund Management — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Shanwan Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Shanwan Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Shanwan Bio
Manufacturer of complex sustained-release dosage forms intended for controlled drug delivery purposes. The company offers in-situ gel matrix technology, peptide and small molecule formulation capabilities, GMP-compliant pilot and commercial production lines including prefilled syringes and lyophilized injectables, CDMO services for formulation development, analytical testing, stability studies, regulatory support, and technology transfer processes, enabling pharmaceutical developers and biopharma partners to accelerate long-acting product development, enhance therapeutic efficacy, ensure quality compliance, and reduce time-to-market.
- Sector
- Healthcare
- HQ
- Suzhou, China
- Founded
- 2018
- Employees
- 1
- Website
- shanwanbiotech.com/
- Ownership
- Privately Held (backing)
Shanwan Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Shanwan Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Shanwan Bio in its N-PORT filings yet. We sweep new filings monthly.